Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Methotrexate induces remission in refractory Crohn's disease

Research reported in this month's Cochrane Database of Systematic Reviews recommends the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's.

News image

fiogf49gjkf04

Although corticosteroids are effective for induction of remission of Crohn's disease, approximately 20% of patients who respond relapse when steroids are withdrawn and become steroid dependent.

Furthermore, corticosteroids exhibit significant adverse effects.

The success of methotrexate as a treatment for rheumatoid arthritis led to its evaluation in patients with refractory Crohn's disease.

Methotrexate has been studied for induction of remission of refractory Crohn's disease and has become the principal alternative to azathioprine/6MP therapy.

The evidence for its effectiveness has not been subjected to a systematic review.

Dr Alfadhli and colleagues conducted a systematic review of the evidence for effectiveness of methotrexate for induction of remission with active Crohn's disease.

The researchers looked at active Crohn’s disease in the presence and absence of concomitant steroid therapy.

3 small studies were identified that used low doses of methotrexate orally
The Cochrane Database of Systematic Reviews

The research team conducted a computer-assisted search of MEDLINE and EMBASE for randomized controlled trials involving patients of age more than 17 years.

The team searched for relevant studies published in English, French, Spanish, Italian and German between 1966 and 2004.

Manual searches of reference lists from potentially relevant papers were performed to identify additional studies.

In addition, the researchers searched the Cochrane Controlled Trials Register as well as the Inflammatory Bowel Disease Review Group Specialized Trials Register.

The team defined refractory Crohn's disease by conventional clinical, radiological and endoscopic criteria, categorized as being active with a disease activity index more than 150.

The outcome measure was the rate of induction of remission and complete withdrawal from steroids in treatment and control groups after more than 16 weeks.

The investigators included a secondary outcome of induction of remission and reduction in steroid dose of at least 50%.

The results of the searches above were reviewed independently by two observers and relevant studies were selected according to the predefined selection criteria.

The team resolved any disagreement by consensus and used a standard data extraction form.

The same two researchers assessed the methodological quality of each trial by considering details of randomization method and whether intention-to-treat analysis was possible from the published data.

The quality of each trial was also assessed by the number of patients lost to follow-up, and whether a blinded outcome assessment was used.

In considering the appropriateness of combining results, the researchers first assessed trials according to the clinical comparability of trial protocols and study populations.

The investigators identified 5 randomized trials and these were considered inappropriate to combine because they differed with respect to participants, intervention, and outcomes.

The team found 3 small studies which employed low doses of methotrexate orally.

The pooled results of these 3 studies showed no statistically significant difference between methotrexate and placebo/control medication treated patients.

The investigators identified 1 small study which used a higher dose of intravenous/oral methotrexate that showed no statistically significant difference.

A larger study which employed a higher dose of methotrexate intramuscularly showed substantial benefit.

The researchers found adverse effects were more common with high dose intramuscular methotrexate therapy than with placebo.

Dr Alfadhli concludes, “There is evidence from a single large randomized trial on which to recommend the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's disease.”

“Although adverse effects were more common than with placebo, they were not severe.”

“There is no evidence on which to base a recommendation for use of lower dose oral methotrexate.”

The Cochrane Database Syst Rev 2005: 2. Art. No.: CD003459.pub2. DOI: 10.1002/14651858.CD003459.pub2.
11 May 2005

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us